A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)-Reference-Cited by-同舟云学术

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

Published:2019-03-14 Issue:1 Volume:19 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Meindl-Beinker Nadja M.^ORCID,Betge Johannes,Gutting Tobias,Burgermeister Elke,Belle Sebastian,Zhan Tianzuo,Schulte Nadine,Maenz Martin,Ebert Matthias P.,Haertel Nicolai

Funder

sponsored by AIO-Studien gGmbH funded by BMS

grants from the State of Baden-Württemberg for “Center of Geriatric Biology and Oncology (ZOBEL) - Perspektivförderung

grants from the State of Baden-Württemberg for “Biology of Frailty - Sonderlinie Medizin”

Medical Faculty Mannheim and the State of Baden-Württemberg

Deutsche Forschungsgemeinschaft within the funding programme Open Access Publishing, by the Baden-Württemberg Ministry of Science, Research and Arts and by Ruprecht-Karls-Universität Heidelberg

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-019-5446-2.pdf

Reference35 articles.

1. Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–73.

2. Okada E, Ukawa S, Nakamura K, Hirata M, Nagai A, Matsuda K, Ninomiya T, Kiyohara Y, Muto K, Kamatani Y, et al. Demographic and lifestyle factors and survival among patients with esophageal and gastric cancer: the biobank Japan project. J Epidemiol. 2017;27(3S):S29–35.

3. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.

4. Thallinger CM, Raderer M, Hejna M. Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol. 2011;29(35):4709–14.

5. Takashi Kojima KM, Francois E, Hsu C-H, Moriwaki T, Kim S-B, Lee S-H, Bennouna J, Kato K, Lin S, Qin S-Q, Ferreira P, Doi T, Adenis A, Enzinger PC, Shah MA, Wang R, Bhagia P, Peter Kang S, Metges J-P. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol. 2019;37(suppl 4):abstr 2.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study;Journal of Geriatric Oncology;2024-09

2. Organoids in gastrointestinal diseases: from bench to clinic;MedComm;2024-06-29

3. Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions;Expert Review of Clinical Immunology;2024-06-17

4. Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage;Pharmaceutics;2024-05-29

5. In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalized cancer therapy: scopes and challenges;Expert Review of Clinical Immunology;2024-04-03